Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2256)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 01.06.24 12:06:46 von
neuester Beitrag 01.06.24 12:06:46 von
Beiträge: 23.378
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 165
Gesamt: 1.263.821
Gesamt: 1.263.821
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVV1
13,866
EUR
-1,62 %
-0,228 EUR
Letzter Kurs 31.05.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
29.05.24 · Felix Haupt Anzeige |
23.05.24 · wallstreetONLINE Redaktion |
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein! 14.05.24 · wallstreetONLINE Redaktion |
14.05.24 · inv3st.de Anzeige |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2554 | +9.943,20 | |
| 7,9600 | +151,90 | |
| 2,3900 | +32,04 | |
| 6,7800 | +30,13 | |
| 3,1100 | +29,05 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,4800 | -17,80 | |
| 9,6000 | -18,64 | |
| 8,6850 | -20,47 | |
| 2,0400 | -58,87 | |
| 0,8020 | -91,06 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 37.845.521 von vanillamilkshake am 25.08.09 13:28:19Die ultraschnelle VLP-Technologie seh ich in Bezug auf ne Mutation des Virus... Dann wären alle bisherigen Anstrengungne der Politik umsonst gewesen... Hohes Risiko
Antwort auf Beitrag Nr.: 37.844.643 von 360 am 25.08.09 12:00:04Ich hab auch gesehen, dass plötzlich richtig Volumen reinkam und dann der Kurs hochging. Ich nehm mal an, dass lag schon irgendwo an den Berichten (um die 90k Todesopfer kamen eine ganze Reihe Pressemeldungen raus), ansonsten wüsste ich nicht, warum plötzlich der kurs so angezogen is...
Naja, ich schlafe besser, wenn ich NVAX im Depot habe. Ultraschnelle VLP-Technologie und ein beschleunigtes Zulassungsverfahren, die nachlässige Pandemiepolitik... Insgesamt ein sehr aussichtsreicher Mix für Kursgewinne...
Good Luck @ all!
Naja, ich schlafe besser, wenn ich NVAX im Depot habe. Ultraschnelle VLP-Technologie und ein beschleunigtes Zulassungsverfahren, die nachlässige Pandemiepolitik... Insgesamt ein sehr aussichtsreicher Mix für Kursgewinne...
Good Luck @ all!
Antwort auf Beitrag Nr.: 37.844.396 von vanillamilkshake am 25.08.09 11:37:13ist aber eigentlich nichts Neues - stellt euch mal vor da wird plötzlich der Name Novavax mal erwähnt, weil die so rasend schnell was herstellen können, nicht zu denken was da kurstechnisch passieren wird
Antwort auf Beitrag Nr.: 37.843.529 von 360 am 25.08.09 10:04:46und der hier:
http://www.thetechtrader.com/closing/1842/
http://www.thetechtrader.com/closing/1842/
Antwort auf Beitrag Nr.: 37.843.529 von 360 am 25.08.09 10:04:46
http://news.yahoo.com/s/afp/20090824/hl_afp/healthfluuswhous…
http://news.yahoo.com/s/afp/20090824/hl_afp/healthfluuswhous…
Trading Spotlight
Antwort auf Beitrag Nr.: 37.837.564 von medding am 24.08.09 13:34:31gestern gegen 19.30 pötzlich reger Handel mit steigenden Kursen, finde aber keine News....ausser ein Inteview mit Novavax:
FOX Business News TV Interview with Rahul Singhvi
FOX Business News TV Interview with Rahul Singhvi
Stille hier. Hat keiner neue Nachrichten bzgl. des Unternehmens-/Forschungsverlauf etc.?????
Antwort auf Beitrag Nr.: 37.809.998 von 360 am 19.08.09 14:18:43und zur Beruhigung einfach den Chart anschauen
egal ob 1-Monatschart oder 5-Jahreschart.
Schaut doch gut aus !
egal ob 1-Monatschart oder 5-Jahreschart.
Schaut doch gut aus !
Antwort auf Beitrag Nr.: 37.807.998 von basset69 am 19.08.09 10:27:20
Kurse um die 52$ stellt euch dies mal vor. Heute ist Vorbörslich wieder mal abverkaufen angesagt. Ich diejenigen, welche auf die Schweinegrippe mit NVAX gehofft haben springen ab. Ich bin mir sicher, dass da noch einiges kommt - aus Indien und dem Rest der Welt.....zwischenzeitlich müssen wir dem Kursgeschehen leider einfach zusehen.
Kurse um die 52$ stellt euch dies mal vor. Heute ist Vorbörslich wieder mal abverkaufen angesagt. Ich diejenigen, welche auf die Schweinegrippe mit NVAX gehofft haben springen ab. Ich bin mir sicher, dass da noch einiges kommt - aus Indien und dem Rest der Welt.....zwischenzeitlich müssen wir dem Kursgeschehen leider einfach zusehen.
Antwort auf Beitrag Nr.: 37.803.581 von 360 am 18.08.09 17:21:09heißt wohl, dass es in Europa bei Bedarf auch schneller gehen kann.
1) Das selbe gilt übrigens auch in Indien (CADILA), wo 12 Wochen
für die Anerkennung vorgesehen sind und das ist noch nicht einmal fast tracked. Das wäre dann November !
http://www.cdsco.nic.in/new%20timeline.pdf
s. auch:
Modi said the vaccine is expected to be available in November 2009 if permission for clinical trial comes from the government immediately. The government has already decided to clear swine flu related applications on fast track basis.
2) Es gibt auch Möglichkeiten außerhalb der Schweinegrippe:
Die VLP PLattform ist geeignet Impfstoffe zu entwickeln gegen Krankheiten wie Hepatitis E, chikungunya-Fieber, dengue Fieber und
Tollwut.
Hepatitis E is a principal cause of hepatitis among adults under 40 years of age, associated with fulminant hepatitis and a mortality rate of up to 20% in infected pregnant
women. Dengue fever is a mosquito-borne disease, which has re-emerged in India. Denguefever is characterized by severe pain in the eyes, head and extremities. It has a very highmortality rate. There is no vaccine or definitive treatment for Dengue fever currently. Rabies is responsible for 25,000 to 30,000 deaths annually in India.
3) Noch eine Möglichkeit zur Dauer der Anerkennung:
The FDA follows very specific rules. The swine flu H1N1 is a subtype of the seasonal flu H1N1 and the Spanish flu H1N1. It's also closely related to the bird flu H5N1. Thus, pandemic or not, companies that have had phase 3 approval for other flu strains and types are required to do a minimal amount of testing (pre-clinical followed by a brief phase 2 or 3). Companies that have not done phase 2 or 3 for any other flu strain, have to go through the entire preclinical and clinical process (several years).
NVAX is somewhere in the middle. They have finished several preclinical studies for all types of flu, one phase 1 and one phase 2 clinical for H5N1, and two phase 2 for the seasonal flu H1N1, H3N2 and B. The safety results were excellent for all and unmatched by any other vaccine, bar none. It's simply trivial and common knowledge that phase 1 would not be required for the swine flu, and that the go-ahead for phase 2 is given very quickly. I should add that this is the case also because NVAX used the exact same technology and process to design and manufacture the swine flu vaccine that they used for past flu vaccines.
4) und noch was zum Träumen:
NVAX is not a direct swine flu play. Its a VLP play. VLPs are
much more effective and cheaper to make than lower quality
traditional vaccines. It's like comparing DVD to VHS. VLPs will be the future of all vaccines. no more chicken eggs.
NVAX has the best VLPs. They pack several proteins on the surface and have the patents to protect it. Merck's Gardasil is like a Ford sedan and NVAX VLPs are like a Rolls Royce.
Swine flu is only one of the vaccines NVAX is making. If you look at the pipeline, you'll notice they have seasonal flu, avian flu, hiv, rsv, etc. seasonal flu alone is a $6 billion per year market.
imagine if NVAX got just a small portion of that market. NVAX has 86 million shares outstanding. lets say they could pull in 10% of the seasonal flu market and lets say half of that were profit. thats earnings per share of 3.50. with a conservative p/e of 15, that would put share
price at $52.50.
and thats being very conservative- only seasonal flu and only 10% of the entire market.
the WHO said swine flu is a $10-20 billion market (depending on number of shots needed, etc.). again, lets say they get 10% of 10B and half were profit. thats EPS of 5.81. with a p/e of 15, share price would be $87.15
1) Das selbe gilt übrigens auch in Indien (CADILA), wo 12 Wochen
für die Anerkennung vorgesehen sind und das ist noch nicht einmal fast tracked. Das wäre dann November !
http://www.cdsco.nic.in/new%20timeline.pdf
s. auch:
Modi said the vaccine is expected to be available in November 2009 if permission for clinical trial comes from the government immediately. The government has already decided to clear swine flu related applications on fast track basis.
2) Es gibt auch Möglichkeiten außerhalb der Schweinegrippe:
Die VLP PLattform ist geeignet Impfstoffe zu entwickeln gegen Krankheiten wie Hepatitis E, chikungunya-Fieber, dengue Fieber und
Tollwut.
Hepatitis E is a principal cause of hepatitis among adults under 40 years of age, associated with fulminant hepatitis and a mortality rate of up to 20% in infected pregnant
women. Dengue fever is a mosquito-borne disease, which has re-emerged in India. Denguefever is characterized by severe pain in the eyes, head and extremities. It has a very highmortality rate. There is no vaccine or definitive treatment for Dengue fever currently. Rabies is responsible for 25,000 to 30,000 deaths annually in India.
3) Noch eine Möglichkeit zur Dauer der Anerkennung:
The FDA follows very specific rules. The swine flu H1N1 is a subtype of the seasonal flu H1N1 and the Spanish flu H1N1. It's also closely related to the bird flu H5N1. Thus, pandemic or not, companies that have had phase 3 approval for other flu strains and types are required to do a minimal amount of testing (pre-clinical followed by a brief phase 2 or 3). Companies that have not done phase 2 or 3 for any other flu strain, have to go through the entire preclinical and clinical process (several years).
NVAX is somewhere in the middle. They have finished several preclinical studies for all types of flu, one phase 1 and one phase 2 clinical for H5N1, and two phase 2 for the seasonal flu H1N1, H3N2 and B. The safety results were excellent for all and unmatched by any other vaccine, bar none. It's simply trivial and common knowledge that phase 1 would not be required for the swine flu, and that the go-ahead for phase 2 is given very quickly. I should add that this is the case also because NVAX used the exact same technology and process to design and manufacture the swine flu vaccine that they used for past flu vaccines.
4) und noch was zum Träumen:
NVAX is not a direct swine flu play. Its a VLP play. VLPs are
much more effective and cheaper to make than lower quality
traditional vaccines. It's like comparing DVD to VHS. VLPs will be the future of all vaccines. no more chicken eggs.
NVAX has the best VLPs. They pack several proteins on the surface and have the patents to protect it. Merck's Gardasil is like a Ford sedan and NVAX VLPs are like a Rolls Royce.
Swine flu is only one of the vaccines NVAX is making. If you look at the pipeline, you'll notice they have seasonal flu, avian flu, hiv, rsv, etc. seasonal flu alone is a $6 billion per year market.
imagine if NVAX got just a small portion of that market. NVAX has 86 million shares outstanding. lets say they could pull in 10% of the seasonal flu market and lets say half of that were profit. thats earnings per share of 3.50. with a conservative p/e of 15, that would put share
price at $52.50.
and thats being very conservative- only seasonal flu and only 10% of the entire market.
the WHO said swine flu is a $10-20 billion market (depending on number of shots needed, etc.). again, lets say they get 10% of 10B and half were profit. thats EPS of 5.81. with a p/e of 15, share price would be $87.15
Durchsuchen
23.05.24 · wallstreetONLINE Redaktion · Pfizer |
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein! 14.05.24 · wallstreetONLINE Redaktion · Sanofi |
10.05.24 · dpa-AFX · McDonald's |
10.05.24 · dpa-AFX · 3M |
10.05.24 · dpa-AFX · Enel |
10.05.24 · dpa-AFX · 3M |
10.05.24 · dpa-AFX · Sanofi |
